Literature DB >> 20434559

Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation.

Michael Dandel1, Hans Brendan Lehmkuhl, Christoph Knosalla, Roland Hetzer.   

Abstract

The introduction of cyclosporine in the early 1980s meant a decisive improvement in post-transplant outcomes for all solid-organ transplants and, in particular, it allowed heart transplantation to emerge as a viable therapeutic option for patients with end-stage cardiac failure. Many factors, including recipient and donor selection, organ preservation and the technical aspects of the transplant itself, influence post-operative outcomes following heart transplantation but the continued need to treat the recipient's immune response plays a key role in determining long-term outcomes. Thereby interactions between immunosuppressive drugs used in different combinations play an important role in patients' outcome. After more than two decades, significant controversy still exists as to the best immunosuppressive regimen for long-term maintenance. During the 1990s and 2000s, newer immunosuppressive medications, specifically, tacrolimus, mycophenolate mofetil, sirolimus, everolimus and the IL-2 receptor blockers (daclizumab and basiliximab), were introduced that allow the clinician several options to try to minimize side effects and maximize the desired therapeutic effects. The side effects involve direct organ toxicity (e.g. renal and hepatic dysfunction), metabolic disturbances, (e.g. diabetes, hyperlipidemia and hypertension), neurotoxicity, and several other significant adverse events, such as cholestasis and myelosuppression. Newer immunosuppressive drugs can impair wound healing, induce lung toxicity and produce various cytopenic states. Steroids continue to plague patients with their well-known side effects. This article reviews the current data on the benefits and risks of the various therapeutic regimens available, which are analyzed under three main themes: calcineurin inhibitor based therapies, calcineurin minimization protocols and calcineurin free regimens. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434559     DOI: 10.1016/j.trim.2010.04.007

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  9 in total

Review 1.  Branched-chain amino acids in metabolic signalling and insulin resistance.

Authors:  Christopher J Lynch; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2014-10-07       Impact factor: 43.330

Review 2.  Local delivery strategies to restore immune homeostasis in the context of inflammation.

Authors:  Elizabeth R Bentley; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-09-13       Impact factor: 15.470

3.  Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions.

Authors:  Ewa Szalowska; Tessa E Pronk; Ad Acm Peijnenburg
Journal:  BMC Genomics       Date:  2015-10-20       Impact factor: 3.969

4.  Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.

Authors:  Ewa Szalowska; Bart van der Burg; Hai-Yen Man; Peter J M Hendriksen; Ad A C M Peijnenburg
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

5.  Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes.

Authors:  Ewa Szalowska; Geert Stoopen; Maria J Groot; Peter J M Hendriksen; Ad A C M Peijnenburg
Journal:  BMC Med Genomics       Date:  2013-10-10       Impact factor: 3.063

Review 6.  Non-invasive cardiac allograft rejection surveillance: reliability and clinical value for prevention of heart failure.

Authors:  Michael Dandel; Roland Hetzer
Journal:  Heart Fail Rev       Date:  2020-09-05       Impact factor: 4.214

Review 7.  Drugs to cure avian influenza infection--multiple ways to prevent cell death.

Authors:  S Yuan
Journal:  Cell Death Dis       Date:  2013-10-03       Impact factor: 8.469

8.  CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients.

Authors:  Máté Déri; Zsófia Szakál-Tóth; Ferenc Fekete; Katalin Mangó; Evelyn Incze; Annamária Minus; Béla Merkely; Balázs Sax; Katalin Monostory
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

9.  De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.

Authors:  Johanna S van Zyl; Teena Sam; Donna M Clark; Joost Felius; Amanda K Doss; Kacie R Kerlee; Zi-On Cheung; Katalin Martits-Chalangari; Aayla K Jamil; Sandra A Carey; Robert L Gottlieb; Cesar Y Guerrero-Miranda; Parag Kale; Shelley A Hall
Journal:  Clin Transplant       Date:  2021-10-01       Impact factor: 3.456

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.